stoxline Quote Chart Rank Option Currency Glossary
  
Takeda Pharmaceutical Company Limited (TAK)
12.6  -0.01 (-0.08%)    06-21 16:00
Open: 12.62
High: 12.71
Volume: 1,693,369
  
Pre. Close: 12.61
Low: 12.6
Market Cap: 39,539(M)
Technical analysis
2024-06-21 4:55:37 PM
Short term     
Mid term     
Targets 6-month :  15.39 1-year :  15.83
Resists First :  13.18 Second :  13.56
Pivot price 13.2
Supports First :  12.57 Second :  10.46
MAs MA(5) :  12.82 MA(20) :  13.16
MA(100) :  13.76 MA(250) :  14.41
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  3.8 D(3) :  14.3
RSI RSI(14): 31.2
52-week High :  16.38 Low :  12.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TAK ] has closed above bottom band by 2.6%. Bollinger Bands are 59.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.74 - 12.81 12.81 - 12.87
Low: 12.41 - 12.52 12.52 - 12.59
Close: 12.47 - 12.62 12.62 - 12.73
Company Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Headline News

Mon, 24 Jun 2024
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV ... - StockTitan

Sat, 22 Jun 2024
Rise Advisors LLC Acquires Shares of 1856 Takeda Pharmaceutical Company Limited (NYSE:TAK) - Defense World

Fri, 21 Jun 2024
Takeda gets EU approval for Fruzaqla for colorectal cancer (NYSE:TAK) - Seeking Alpha

Wed, 19 Jun 2024
Goldman Sachs Group Inc. Sells 547,250 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) - MarketBeat

Wed, 19 Jun 2024
Goldman Sachs Group Inc. Sells 547250 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) - Defense World

Tue, 11 Jun 2024
Takeda Pharmaceutical Unveils Employee Incentive Plan - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 35,080 (M)
Shares Float 0 (M)
Held by Insiders 3.14e+009 (%)
Held by Institutions 1.55e+009 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 1.09
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 299 %
Operating Margin 3.3 %
Return on Assets (ttm) -7.5 %
Return on Equity (ttm) 1.5 %
Qtrly Rev. Growth 4.2 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 11.55
PEG Ratio 219
Price to Book value 0
Price to Sales 2.08494e+011
Price to Cash Flow 1.10502e+011
Stock Dividends
Dividend 6.49e+006
Forward Dividend 5.97e+006
Dividend Yield 51507900%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android